TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
InhaleRx Limited ( (AU:IRX) ) has shared an update.
InhaleRx Limited has announced the issuance of performance rights and options to its Chief Scientific Officer, Dr. Rob Jenny, as part of an incentive plan aligned with key deliverables in their ongoing clinical trials for IRX-211 and IRX-616a. This strategic move is designed to align the CSO’s efforts with shareholder interests and ensure the successful progression of their clinical trials, which are crucial for the company’s growth and market positioning.
More about InhaleRx Limited
InhaleRx Limited is an Australian clinical stage drug development company focused on developing rapid onset inhaled therapies for unmet medical needs in pain management and mental health sectors. The company is working on obtaining U.S. FDA approval for its treatments, IRX-211 for Breakthrough Cancer Pain and IRX-616a for Panic Disorder, using efficient regulatory pathways. InhaleRx has secured a funding partner to support these developments, aiming to address critical gaps in current treatment options.
Average Trading Volume: 206,709
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$6.32M
For a thorough assessment of IRX stock, go to TipRanks’ Stock Analysis page.